Source:http://linkedlifedata.com/resource/pubmed/id/19709980
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2009-11-25
|
| pubmed:abstractText |
Our objective was to study the clinical and management differences between primary and interferon (IFN)-induced depressive disorders in malignant melanoma patients visited by the consultation-liaison team during a two year period. This was a prospective study of 31 patients with malignant melanoma treated with IFN-alpha in a general teaching hospital. Clinical, psychiatric variables and DSM-IV-TR diagnosis were analyzed. The Clinical Global Impression Severity (CGI-S) and Improvement (CGI-I) of illness scales were administered at the time of consultation and at the end of hospitalization. The main diagnoses were depressive adjustment disorders in 14 patients (45.16%) followed by interferon-induced depressive disorders in 6 (19.36%). In patients with adjustment disorders, melanoma stage was significantly more advanced than in those with interferon-induced depressive disorder (p = 0.019). The latter scored higher in the CGI-S scale (p = 0.044) and in the CGI-I scale (p = 0.029). The interferon-induced depressive disorders, except one who required a reduction of IFN-alpha-2b dose, were successfully treated with antidepressant drugs. Clinical management and antidepressant treatment allowed the continuation of interferon therapy in malignant melanoma patients. Interferon-induced depression occurred in a few patients, which in turn were the most severe. Adjustment depressive disorder was the most common psychiatric diagnosis.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Psychotropic Drugs,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/interferon alfa-2b
|
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1167-1122
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
19
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
611-5
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:19709980-Adult,
pubmed-meshheading:19709980-Aged,
pubmed-meshheading:19709980-Antineoplastic Agents,
pubmed-meshheading:19709980-Anxiety,
pubmed-meshheading:19709980-Depression,
pubmed-meshheading:19709980-Depressive Disorder,
pubmed-meshheading:19709980-Female,
pubmed-meshheading:19709980-Hospitals, Teaching,
pubmed-meshheading:19709980-Humans,
pubmed-meshheading:19709980-Inpatients,
pubmed-meshheading:19709980-Interferon-alpha,
pubmed-meshheading:19709980-Male,
pubmed-meshheading:19709980-Melanoma,
pubmed-meshheading:19709980-Mental Disorders,
pubmed-meshheading:19709980-Middle Aged,
pubmed-meshheading:19709980-Prospective Studies,
pubmed-meshheading:19709980-Psychiatric Status Rating Scales,
pubmed-meshheading:19709980-Psychotropic Drugs,
pubmed-meshheading:19709980-Questionnaires,
pubmed-meshheading:19709980-Recombinant Proteins,
pubmed-meshheading:19709980-Severity of Illness Index,
pubmed-meshheading:19709980-Skin Neoplasms,
pubmed-meshheading:19709980-Treatment Outcome
|
| pubmed:articleTitle |
Depression in hospitalized patients with malignant melanoma treated with interferon-alpha-2b: primary to induced disorders.
|
| pubmed:affiliation |
Unitat de Recerca Farmacològica, Institut Municipal d'Investigació Mèdica, Doctor Aiguader 88, E-08003, Barcelona, Spain. rnavines@hotmail.com
|
| pubmed:publicationType |
Journal Article
|